On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...